2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06C.01 KRAS Q61H Mutation Defines a Distinct Clinicopathological Entity of Lung Adenocarcinomas in East Asian Patients

EP.06C.01 KRAS Q61H Mutation Defines a Distinct Clinicopathological Entity of Lung Adenocarcinomas in East Asian Patients

Back to course

Pdf Summary

The study investigates the KRAS Q61H mutation in lung adenocarcinomas among East Asian patients, a population with a lower overall incidence of KRAS mutations. A total of 1,364 non-small cell lung cancer patients underwent broad-panel targeted next-generation sequencing, and 176 invasive lung adenocarcinomas were identified with KRAS mutations. The study focuses on 18 cases with the Q61H mutation, representing 10.2% of the cases examined.<br /><br />Key findings include that the KRAS Q61H mutation frequently co-occurs with STK11 mutations and correlates with lower PD-L1 expression, predominantly affecting the non-mucinous subtype of lung adenocarcinoma. This mutation has significant clinical outcomes, as it is associated with worse overall survival and shorter progression-free survival in patients treated with first-line chemo-immunotherapy. Specifically, in survival analysis, the Q61H mutation demonstrated a hazard ratio of 5.0412, indicating a significantly increased risk of poor outcomes compared to other KRAS mutations.<br /><br />The researchers conclude that the KRAS Q61H mutation defines a distinct clinico-pathological entity of lung adenocarcinomas in East Asian patients, emphasizing the mutation's association with a worse prognosis. The study highlights the necessity for clinicians to consider this mutation when developing treatment plans. Further research may be warranted to explore targeted therapies for patients with this specific mutation. The study was supported by the National Research Foundation of Korea, showcasing an important step in understanding the genetic underpinnings of lung cancer in East Asian populations and its implications for personalized medicine.

Asset Subtitle

Hyo Sup Shim

Meta Tag

Speaker Hyo Sup Shim

Topic Pathology and Biomarkers

Keywords

KRAS Q61H mutation

lung adenocarcinoma

East Asian patients

next-generation sequencing

STK11 mutations

PD-L1 expression

non-mucinous subtype

chemo-immunotherapy

hazard ratio

personalized medicine